<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270011401738</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270011401738</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Authors’ Response</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Erdeve</surname><given-names>Omer</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Atasay</surname><given-names>Begum</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Arsan</surname><given-names>Saadet</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Türmen</surname><given-names>Tomris</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0091270011401738">Omer Erdeve, 10 Cadde Agacseven Sok. 16B/46 06830 Cayyolu Ankara, Turkey; e-mail: <email>omererdeve@yahoo.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>3</issue>
<fpage>447</fpage>
<lpage>447</lpage>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Neonatologists frequently diagnose gastroesophageal reflux (GER) in premature infants, perceive it to be problematic, and prescribe antireflux medications. Twenty-five percent of all extremely low birth weight (ELBW) infants in a cohort and as many as 90% in some nurseries were discharged from the hospital with antireflux medications.1 Although antireflux medications, like so many medications used commonly in neonatal intensive care units (NICUs), have not been approved for use in newborns, they are used in an off-label manner because of the perceived safety and potential benefits demonstrated for older populations.<sup><xref ref-type="bibr" rid="bibr1-0091270011401738">1</xref></sup> Alginate-based formulations are being used for the same purpose in term infants and premature infants, but the frequency of use is not known in the absence of an epidemiological study.<sup><xref ref-type="bibr" rid="bibr2-0091270011401738">2</xref>-<xref ref-type="bibr" rid="bibr4-0091270011401738">4</xref></sup></p>
<p>Our reported study evaluated the efficacy of aluminum-free sodium alginate on pH meter monitoring–defined reflux events and symptoms in preterm infants who were hospitalized in the NICU, showing that it significantly reduced GER parameters and affected the related symptoms.<sup><xref ref-type="bibr" rid="bibr5-0091270011401738">5</xref></sup> The dose of the drug used in our study was determined by the lowest dose reported by previous studies in infants.<sup><xref ref-type="bibr" rid="bibr3-0091270011401738">3</xref>,<xref ref-type="bibr" rid="bibr4-0091270011401738">4</xref></sup> Although pH-meter monitoring, which was determined to show possible efficacy, was performed 48 hours after the administration of the drug, patients were followed for possible side effects and none except thickening of stool in 3 patients were observed. Patients were also evaluated for vomiting and weight gain after the treatment. Patients who responded to treatment continued to receive the drug during hospitalization and postdischarge period depending on the neonatologist’s decision.</p>
<p>A recent study that evaluated the effect of sodium alginate on GER features in preterm newborns by combined pH and impedance monitoring demonstrated that sodium alginate significantly decreased the number of cases of acid GER and number of cases in which GER reached the proximal esophagus. The authors commented that the efficacy of sodium alginate in lowering reflux height could be particularly relevant in preterm infants given the complex and intriguing relationship between GER and respiratory diseases in this population.<sup><xref ref-type="bibr" rid="bibr6-0091270011401738">6</xref></sup> No studies on this topic have been performed, but we believe that ours and similar studies will stimulate larger investigations to clarify the subject. Further work is needed in this field to identify optimal treatment regimes, and until this is achieved clinicians will continue to work with limited options.</p>
<sig-block>
<sig>Omer Erdeve<break/>
<italic>Neonatology Division, Zekai Tahir Burak</italic><break/>
<italic>Maternity Teaching Hospital, Turkey</italic></sig>
<sig>Begum Atasay, Saadet Arsan, and Tomris Türmen<break/>
<italic>Neonatology Division, Ankara University</italic>,<break/>
<italic>School of Medicine, Turkey</italic></sig>
</sig-block>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270011401738">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malcolm</surname><given-names>WF</given-names></name>
<name><surname>Gantz</surname><given-names>M</given-names></name>
<name><surname>Martin</surname><given-names>RJ</given-names></name>
<name><surname>Goldstein</surname><given-names>RF</given-names></name>
<name><surname>Goldberg</surname><given-names>RN</given-names></name>
<name><surname>Cotten</surname><given-names>CM</given-names></name>
</person-group>; <collab>National Institute of Child Health and Human Development Neonatal Research Network</collab>. <article-title>Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants</article-title>. <source>Pediatrics</source>. <year>2008</year>;<volume>121</volume>:<fpage>22</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr2-0091270011401738">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vandenplas</surname><given-names>Y</given-names></name>
<name><surname>Salvatore</surname><given-names>S</given-names></name>
<name><surname>Hauser</surname><given-names>B</given-names></name>
</person-group>. <article-title>The diagnosis and management of gastro-oesophageal reflux in infants</article-title>. <source>Early Hum Dev</source>. <year>2005</year>;<volume>81</volume>:<fpage>1011</fpage>-<lpage>1024</lpage>.</citation>
</ref>
<ref id="bibr3-0091270011401738">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>S</given-names></name>
</person-group>. <article-title>Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux</article-title>. <source>Curr Med Res Opin</source>. <year>1999</year>;<volume>15</volume>: <fpage>160</fpage>-<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr4-0091270011401738">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Le Luyer</surname><given-names>B</given-names></name>
<name><surname>Mougenot</surname><given-names>JF</given-names></name>
<name><surname>Mashako</surname><given-names>L</given-names></name>
</person-group>. <article-title>Multicenter study of sodium alginate in the treatment of regurgitation in infants</article-title>. <source>Ann Pediatr (Paris)</source>. <year>1992</year>;<volume>39</volume>:<fpage>635</fpage>-<lpage>640</lpage>.</citation>
</ref>
<ref id="bibr5-0091270011401738">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Atasay</surname><given-names>B</given-names></name>
<name><surname>Erdeve</surname><given-names>O</given-names></name>
<name><surname>Arsan</surname><given-names>S</given-names></name>
<name><surname>Türmen</surname><given-names>T</given-names></name>
</person-group>. <article-title>Effect of sodium alginate on acid gastroesophageal reflux disease in preterm infants: a pilot study</article-title>. <source>J Clin Pharmacol</source>. <year>2010</year>;<volume>50</volume>:<fpage>1267</fpage>-<lpage>1272</lpage>.</citation>
</ref>
<ref id="bibr6-0091270011401738">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Corvaglia</surname><given-names>L</given-names></name>
<name><surname>Aceti</surname><given-names>A</given-names></name>
<name><surname>Mariani</surname><given-names>E</given-names></name>
<name><surname>De Giorgi</surname><given-names>M</given-names></name>
<name><surname>Capretti</surname><given-names>MG</given-names></name>
<name><surname>Faldella</surname><given-names>G</given-names></name>
</person-group>. <article-title>The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2010</year>;<volume>33</volume>:<fpage>466</fpage>-<lpage>470</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>